MEENAKSHI HEGDE to Neoplasms
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Neoplasms.
Connection Strength
0.292
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
Score: 0.084
-
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
Score: 0.080
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.067
-
Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.
Score: 0.061